Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

80.0%

-6.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 1

4(57.1%)

N/A

3(42.9%)

7Total

Phase 1(4)

N/A(3)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT06068075Not ApplicableActive Not Recruiting

Liquid Biopsy in Ewing Sarcoma and Osteosarcoma as a Prognostic And Response Diagnostic: LEOPARD

Role: collaborator

NCT05660408Phase 1Active Not Recruiting

RNA Lipid Particles Targeting Pediatric Recurrent Intracranial Malignancies and Other systEmic Solid Tumors

Role: collaborator

NCT06156410Phase 1Recruiting

Cabozantinib With Ifosfamide in Relapsed/Refractory Sarcomas

Role: collaborator

NCT01050296Recruiting

Molecular Analysis Of Solid Tumors

Role: collaborator

NCT03139331Phase 1Completed

PAZIT Study for Children and Young Adults With Relapsed or Refractory Sarcoma

Role: collaborator

NCT03279055Not ApplicableCompleted

Web-based Insomnia Treatment for Adolescent and Young Adult Cancer Survivors

Role: collaborator

NCT02603692Completed

Health Related Quality of Life in Pediatric Central Nervous System (CNS) Tumors: A Feasibility Study Utilizing PROMIS

Role: collaborator

NCT02439788Phase 1Withdrawn

3RD GENERATION GD2 SPECIFIC CHIMERIC ANTIGEN RECEPTOR TRANSDUCED AUTOLOGOUS NATURAL KILLER T-CELLS FOR NEUROBLASTOMA

Role: collaborator

NCT00862186Not ApplicableCompleted

Self-Management of Cancer-Related Fatigue by Adolescents

Role: collaborator

All 9 trials loaded